The coronavirus pandemic has done little to hamper the growth trajectory of the bioprocess engineering leader.
News & Analysis: Repligen
Investors have come to value the company's resilience in an uncertain year.
RGEN earnings call for the period ending March 31, 2020.
The bioprocess equipment leader didn't see a slowdown from the coronavirus pandemic, while expected headwinds in a major business unit failed to materialize.
The bioprocess leader relies on clinical trials for a significant portion of revenue. How disruptive will the coronavirus be?
The bioprocess company was a rare bright spot for investors, although the worst is likely yet to come for the stock.
These two stocks can be used to gauge how the pharmaceutical industry and energy sector are faring during the coronavirus pandemic -- and what might be ahead.
The biotechnology supplier ended a tough week with a bang.
Drilling down in the numbers shows how the bioprocess leader became one of the best growth stocks on the market -- and how it remains well-positioned for long-term growth.
Guidance for 2020 appears to have spooked investors, but the bioprocess leader is on a solid long-term trajectory.